Searchable abstracts of presentations at key conferences in endocrinology

ea0032p828 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 pituitary adenomas, using immunohistochemical detection with specific MABs

Chinezu Laura , Vasiljevic Alexandre , Jouanneau Emmanuel , Francois Patrick , Borda Angela , Raverot Gerald , Trouillas Jacqueline

Background: Medical treatment of pituitary adenomas with somatostatin analogs depends on tumor type and somatostatin receptor expression. Using polyclonal antibodies, their immunohistochemical (IHC) detection gave conflicting results. Therefore, we studied the IHC expression of SSTR2A and SSTR5 using two specific MABs in five types of pituitary adenomas.Methods: SSTR2A and SSTR5 expression was studied using two...

ea0022p383 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

Raverot Gerald , Sturm Nathalie , De Fraipont Florence , Caron Philippe , Muller Marie , Cortet-Rudelli Christine , Salenave Sylvie , Assaker Richard , Dufour Henry , Gaillard Stephan , Francois Patrick , Jouanneau Emmanuel , Bernier Michele , Figarella-Branger Dominique , Maurage Claude-Alain , Trouillas Jacqueline , Borson-Chazot Francoise , Brue Thierry

Context: To date ten publications reporting only 16 patients with pituitary aggressive tumors or carcinomas treated with temozolomide are available. Expression of O6-methylguanine-DNA-methyltranferase (MGMT), a DNA repair protein implicated in the resistance to temozolomide, was studied in only 10 out of these 16 patients. It has been suggested that low expression of MGMT could predict temozolomide efficacy.Objective: The aim of this st...